Selective Lipopolysaccharide Hemosorption in Maternal Sepsis

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

June 15, 2024

Conditions
Maternal sepsIs
Interventions
DEVICE

Efferon LPS

Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 12h immediately following admission to the intensive care unit

Trial Locations (7)

Unknown

Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk

Moscow Regional Perinatal Center, Moscow

National Medical Research Center named after V.I. Kulakov, Moscow

Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko, Nizhny Novgorod

Perm regional clinical hospital, Perm

Surgut District Clinical Center for Maternity and Childhood Health, Surgut

Perinatal Center of the Tyumen Region, Tyumen

All Listed Sponsors
lead

Efferon JSC

INDUSTRY

NCT05711901 - Selective Lipopolysaccharide Hemosorption in Maternal Sepsis | Biotech Hunter | Biotech Hunter